AstraZeneca Earnings, Sales Rise, Beating Forecasts — Update
By Helena Smolak
AstraZeneca posted increased first-quarter core earnings per share and sales that beat forecasts.
The Anglo-Swedish pharmaceutical giant said Thursday that its core earnings per share increased to $2.06 from $1.92 the prior-year period.
At 0910 GMT, Shares of AstraZeneca traded 5.2% higher at 11,940 pence. The stock was up 13% year to date but down 2.9% on year.
Total revenue rose 19% to $12.68 billion boosted by product sales and continued growth in alliance revenue from partnered medicines which could offset waning demand for its Covid-19 products. Its oncology segment, the drugmaker's top business, grew 26% to $5.11 billion.
Analysts expected core earnings per share of $1.92 on sales of $11.84 billion, according to a company-compiled consensus.
AstraZeneca reiterated its full-year guidance and said it is increasing investment in its pipeline with research and development expenses climbing by 17% in the first quarter.
Write to Helena Smolak at helena.smolak@wsj.com
(END) Dow Jones Newswires
April 25, 2024 05:42 ET (09:42 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
After Earnings, Is Lyft Stock a Buy, a Sell, or Fairly Valued?
-
8 Stock Picks in the Apparel Industry
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?
-
Walmart Earnings: Low Prices and Strong Digital Presence Drive Market Share Gains
-
After Earnings and a Big Selloff, Is Shopify Stock a Buy, a Sell, or Fairly Valued?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing